Cart
sales@molnova.com
EX-A5386
CAS No. 2452396-89-1
EX-A5386( —— )
Catalog No. M35951 CAS No. 2452396-89-1
EX-A5386 (Glucocorticoid receptor modulator-1) is a potent glucocorticoid receptor modulator, IC50/EC50<100nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 135 | Get Quote |
|
| 5MG | 202 | Get Quote |
|
| 10MG | 306 | Get Quote |
|
| 25MG | 495 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEX-A5386
-
NoteResearch use only, not for human use.
-
Brief DescriptionEX-A5386 (Glucocorticoid receptor modulator-1) is a potent glucocorticoid receptor modulator, IC50/EC50<100nM.
-
DescriptionGlucocorticoid receptor modulator 2 (Example 1) is a glucocorticoid receptor modulator, with an IC50 value less than 100 nM. Glucocorticoid receptor modulator 2 can be used for research of inflammatory and immune diseases.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorGlucocorticoid Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2452396-89-1
-
Formula Weight482.55
-
Molecular FormulaC29H27FN4O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C(=O)C1CC1)[C@@H]2[C@H](N(C(=O)C2(C)C)C=3C=C4C(=CC3)N(N=C4)C5=CC=C(F)C=C5)C6=CC=CC=C6
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Florian JAKOB, et al. Substituted pyrrolidine amides iii. Patent. WO2020144375.
molnova catalog
related products
-
Aristolone
Aristolone has potential anti-cancer activity.
-
Mulberroside F
Mulberroside F shows inhibitory effects on tyrosinase activity and on the melanin formation of melan-a cells, it also exhibits superoxide scavenging activity that is involved in the protection against auto-oxidation, suggests that mulberroside F may be used as a skin whitening agent.
-
WDR5-0102
WDR5-0102 is a compound that inhibits the WDR5-MLL1 interface (K dis = 7 μM, K d = 4 μM), selectively reducing MLL1 HMT activity without affecting the human H3K4 methyltransferase SETD7 or other HMTs, including G9a, EHMT1, SUV39H2, SETD8, PRMT3, and PRMT5.
